OpGen-image

OpGen

US: OPGN

Market Cap$98.3m

Last Close $2.45

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

More OpGen content >

Investment summary

OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. It recently merged with Curetis, a Germany-based molecular diagnostics company with a complementary focus on infectious disease. Curetis has two main business lines: the Unyvero A50 high-plex polymerase chain reaction platform for the diagnosis of infectious disease in hospital patients and the ARES AMR database (ARESdb), which includes data on 55,000 sequenced strains with a focus on resistant pathogens, as well as data on over 100 antibiotics.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 3.5 (11.7) (11.9) (737.6) N/A N/A
2020A 4.2 (22.0) (25.3) (157.4) N/A N/A
2021E 3.3 (27.8) (32.5) (89.8) N/A N/A
2022E 16.6 (18.8) (21.1) (51.8) N/A N/A
Industry outlook

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Last updated on 18/08/2021
Content on OpGen
OpGen – AMR Gene Panel clearance expected shortly
Healthcare | Update | 18 August 2021
OpGen-image
OpGen – Q121 results
Healthcare | Update | 19 May 2021
OpGen-image
View more
Register to receive research on OpGen as it is published
Share price graph
Balance sheet
Forecast net debt (US$m) 7.2
Forecast gearing ratio (%) 30
Price performance
%
1m
3m
12m
Actual 10.3 11.3 (23.7)
Relative* 8.7 6.2 (42.3)
52-week high/low US$2.2/US$0.2
*% relative to local index
Key management
Oliver Schacht CEO